{"id":596,"date":"2023-09-08T13:00:00","date_gmt":"2023-09-08T04:00:00","guid":{"rendered":"https:\/\/www.sonire-therapeutics.com\/?p=596"},"modified":"2025-11-25T19:36:01","modified_gmt":"2025-11-25T10:36:01","slug":"nedo_grant","status":"publish","type":"post","link":"https:\/\/www.sonire-therapeutics.com\/en\/nedo_grant\/","title":{"rendered":"Notice of Adoption being seleced for \u201cDeep Tech Startup Support Program\u201d by New Energy and Industrial Technology Development Organization (NEDO)"},"content":{"rendered":"\n<p>SONIRE Therapeutics Inc. (Headquarters: Shinjuku-ku, Tokyo; President and CEO, Co-<br>Founder: Tohru Satoh; hereinafter referred to as &#8220;SONIRE&#8221;), announces that our project<br>&#8220;Research and Development of Next-Generation Focused Ultrasound Therapy System for<br>Intractable Cancer&#8221; has been selected for the PCA (Product Commercialization Alliance)<br>phase of the Deep Tech Startup Support Program implemented by New Energy and Industrial<br>Technology Development Organization (NEDO).<br><br>The adoption of this program will further accelerate the development of our &#8220;next-generation<br>HIFU (High-Intensity Focused Ultrasound) therapy device&#8221;.<br><br>We will continue to promote our business in order to realize the wish we put in our company<br>name at the time of our foundation: &#8221; Sonics\uff08Ultrasound\uff09 Brings New Future to Cancer<br>Patients and their Families.&#8221;.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.sonire-therapeutics.com\/wp-content\/uploads\/2023\/09\/SONIRE_News-Release_NEDO_Grant-230907_EN.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Download PDF file<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SONIRE Therapeutics Inc. (Headquarters: Shinjuku-ku, Tokyo; President and CEO, Co-Founder: Tohru Satoh; hereinafter referred to as &#8220;SONIRE&#8221;), announces that our project&#8220;Research and Development of Next-Generation Focused Ultrasound Therapy System forIntractable Cancer&#8221; has been selected for the PCA (Product Commercialization Alliance)phase of the Deep Tech Startup Support Program implemented by New Energy and IndustrialTechnology Development Organization [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_locale":"en_US","_original_post":"https:\/\/www.sonire-therapeutics.com\/?p=588","footnotes":""},"categories":[15],"tags":[],"class_list":["post-596","post","type-post","status-publish","format-standard","hentry","category-grand","en-US"],"_links":{"self":[{"href":"https:\/\/www.sonire-therapeutics.com\/wp-json\/wp\/v2\/posts\/596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sonire-therapeutics.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sonire-therapeutics.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sonire-therapeutics.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sonire-therapeutics.com\/wp-json\/wp\/v2\/comments?post=596"}],"version-history":[{"count":3,"href":"https:\/\/www.sonire-therapeutics.com\/wp-json\/wp\/v2\/posts\/596\/revisions"}],"predecessor-version":[{"id":600,"href":"https:\/\/www.sonire-therapeutics.com\/wp-json\/wp\/v2\/posts\/596\/revisions\/600"}],"wp:attachment":[{"href":"https:\/\/www.sonire-therapeutics.com\/wp-json\/wp\/v2\/media?parent=596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sonire-therapeutics.com\/wp-json\/wp\/v2\/categories?post=596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sonire-therapeutics.com\/wp-json\/wp\/v2\/tags?post=596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}